Ewch i’r prif gynnwys

Newyddion

Mae'r cynnwys hwn ar gael yn Saesneg yn unig.

Nid yw arllwys ychwanegion meddalhaol mewn bath yn cynnig unrhyw fantais o'i gymharu â'r dulliau arferol ar gyfer rheoli ecsema, yn ôl astudiaeth newydd gan dîm sy'n cynnwys ymchwilwyr o Brifysgol Caerdydd.

Yn y prawf mwyaf hyd yma o ychwanegion bath meddalhaol, cafodd 482 o blant eu rhoi mewn dau grŵp: gofynnwyd i un grŵp ddefnyddio ychwanegion bath am flwyddyn gyfan, a gofynnwyd i'r llall beidio â'u defnyddio. Cwblhaodd teuluoedd holiaduron byr bob wythnos am y 16 wythnos gyntaf, yna pob 4 wythnos rhwng 16 a 52 wythnos.

Dangosodd y canlyniadau nad oedd gwahaniaeth o bwys yn nifrifoldeb yr ecsema rhwng y ddau grŵp. Nid oedd gwahaniaeth chwaith yn nifer y problemau a gafwyd wrth ymolchi, fel poen neu groen coch ar ôl bath, a effeithiodd ar un rhan o dair o'r plant yn y ddau grŵp.

Dywedodd Dr Nick Francis, Darllenydd Clinigol ym Mhrifysgol Caerdydd sydd hefyd yn gweithio fel meddyg teulu: "Mae ychwanegion meddalhaol ar gyfer y bath yn aml yn cael eu defnyddio i reoli ecsema, ond mae ein hastudiaeth yn dangos nad ydynt yn debygol o gynnig unrhyw fantais."

Ychwanegodd Dr Miriam Santer o Brifysgol Southampton, arweinydd yr astudiaeth: "Dylai teuluoedd plant gydag ecsema barhau i ddefnyddio lleithydd meddalhaol sy'n cael ei adael ymlaen, ac osgoi sebon."

Mae'r dulliau safonol ar gyfer rheoli ecsema ymhlith plant yn cynnwys defnyddio opsiynau eraill yn lle sebon, lleithyddion sy'n cael eu gadael ymlaen, ac eli corticosteroidau.

Cafodd y treial BATHE ei ariannu gan Raglen Asesu Technoleg Iechyd NIHR a'i arwain gan Brifysgol Southampton mewn partneriaeth â Phrifysgol Bryste, Prifysgol Caerdydd a Phrifysgol Nottingham.

Gwyliwch grynodeb byr:  https://youtu.be/tpgnNOhXgl8

Neu ewch i wefan yr astudiaeth: https://www.southampton.ac.uk/bathe

Mae’r Athro Julia Sanders wedi ennill grant o £900,000 i arwain astudiaeth sy’n archwilio diogelwch geni mewn dŵr i famau a babanod.

Dros yr ugain mlynedd diwethaf, mae geni mewn dŵr wedi dod yn fwyfwy poblogaidd yn y DU. Mae llawer o fenywod bellach yn defnyddio pwll wrth eni i leddfu poen, ac mae rhai, hyd at 60,000 o fenywod y flwyddyn yn y DU o bosibl, yn dewis aros yn y pwll er mwyn geni eu babanod.

Mae gan lawer o weithwyr proffesiynol a rhieni safbwyntiau cryf ar eni mewn dŵr. Mae rhai yn eiriolwyr mawr, gan hyrwyddo’r manteision, tra bo eraill yn dal i bryderu y gallai menywod sy'n geni mewn dŵr fod yn peri risgiau ychwanegol diangen i’w hunain a’u babanod.

Meddai Julia Sanders, Athro Nyrsio Clinigol a Bydwreigiaeth, sy'n gweithio ar y cyd rhwng Ysgol y Gwyddorau Gofal Iechyd, Prifysgol Caerdydd a Bwrdd Iechyd Prifysgol Caerdydd a’r Fro: "Mae'r rhan fwyaf o unedau mamolaeth yn y DU bellach yn cynnig geni mewn dŵr fel dewis i fenywod, ond nid oes astudiaeth digon mawr wedi’i chynnal hyd yn hyn i ddangos a yw geni mewn dŵr yr un mor ddiogel i famau a babanod â defnyddio pwll i leddfu poen wrth eni, cyn camu allan cyn geni.

Mae’r astudiaeth PWLL (POOL study) yn bwriadu ateb y cwestiwn pwysig hwn am ddiogelwch geni mewn  dŵr. Bydd yr astudiaeth yn cynnwys data o enedigaethau yn ystod y cyfnod chwe blynedd rhwng 2015 a 2020 mewn oddeutu 30 o unedau mamolaeth y GIG, a chymharu canlyniadau o 15,000 o enedigaethau dŵr â 15,000 o enedigaethau y tu allan i'r dŵr.

Fel yr esboniodd Abi Holmes, Bydwraig Ymgynghorol sy’n gweithio yng Nghaerdydd ac sy’n un o gyd-ymgeiswyr y grant: "Mae'n bwysig ein bod yn cynnal yr astudiaeth hon heb amharu ar fenywod sy’n geni neu newydd eni. Am y rheswm hwn, bydd yr astudiaeth yn defnyddio gwybodaeth a gesglir fel rhan o gofnod mamolaeth pob menyw sy’n cael ei storio ar systemau cyfrifiadurol mewn ysbytai. Ar gyfer babanod sydd angen gofal arbenigol ar ôl iddynt gael eu geni, bydd yr astudiaeth hefyd yn defnyddio data a gedwir yn y Gronfa Ddata Newyddenedigol Genedlaethol."

Meddai Billie Hunter, Athro Bydwreigiaeth yng Ngholeg Brenhinol y Bydwragedd, a fydd yn arwain ar y maes astudio i archwilio pam fod gan rai unedau mamolaeth gyfraddau uwch o enedigaethau mewn dŵr nag eraill: "Mae cael babi bob amser yn gyfnod arbennig ac mae angen gwybodaeth ar rieni i wneud y dewisiadau gorau, i’w hunain a’u babanod. Mae'r astudiaeth bwysig hon yn dwyn ynghyd arweinwyr mewn bydwreigiaeth, obstetreg, neonatoleg, ac ynghyd â staff o Ganolfan Treialon Ymchwil Prifysgol Caerdydd, a’r NCT sy'n cynrychioli rhieni, byddwn yn cynhyrchu gwybodaeth newydd ar eni mewn dŵr fel y gall rhieni’r dyfodol wybod mwy am yr opsiynau wrth eni."

Mae’r astudiaeth yn cael ei hariannu gan yr NIHR NTA, prosiect 16/149/01 – The POOL Study. I gael rhagor o wybodaeth, cysylltwch â sandersj3@cf.ac.uk neu poolstudy@cardiff.ac.uk

Many men experience Lower Urinary Tract Symptoms (LUTS) as they get older. Problems include passing urine more frequently than usual which can interrupt sleep, or experiencing a poor flow rate. Although GPs follow certain processes when considering serious conditions or cancer, there is currently no single effective way to identify and treat LUTS in primary care. Men are increasingly referred to urology specialists who often recommend treatments that could have been initiated in primary care (care provided by GPs, before being referred to a hospital), if GPs had access to better diagnostic tools.

Access to simple, accurate tests, diagnostic protocols and decision tools are needed to facilitate patient management in primary care.

The PriMUS study run by the Centre for Trials Research at Cardiff University aims to develop a clinical decision support tool based on symptoms, signs, patient characteristics and tests that can be done in primary care - predominantly following National Institute for Health and Care Excellence (NICE) guidelines. These features and tests will be compared to the current ’gold standard’ test used to predict the cause of LUTS in secondary care: urodynamics. Urodynamics involves passing catheters into the bladder and rectum in order to make precise measurements regarding bladder function. The clinical decision support tool will be a computer software programme, which will indicate likely diagnosis and recommended management options for the GP to discuss with patients.

The PriMUS study will recruit 880 male participants across three research hubs based in Newcastle upon Tyne, Bristol and Wales. Participants will be recruited opportunistically, upon presentation with LUTS to the GP, or invited to take part in the study by screening patient notes for eligibility.

All participants will undergo a series of primary care tests and the invasive urodynamics test, within a few weeks of seeing their GP. This study has the potential to give patients early access to appropriate treatments (e.g. medication, lifestyle changes) and to reduce referrals and the pressure on secondary care urology services. Additionally, those who need urgent referral for more complex or serious conditions will benefit from reduced waiting lists.

The PriMUS Study opened for patient recruitment in general practices on 19 February 2018.

The study is funded by the NIHR Health Technology Assessment programme.

Bydd Prifysgol Caerdydd yn cael hwb ariannol mawr am waith arloesol ynghylch canser.

Mae Ymchwil Canser y DU yn bwriadu buddsoddi dros £5.5m dros y bum mlynedd nesaf mewn gwaith arloesol yn y Ganolfan Treialon Ymchwil.

Bydd y grant yn galluogi meddygon a gwyddonwyr barhau i ymchwilio a phrofi well ac yn fwy caredig triniaethau ar gyfer cleifion.

Mae Canolfan Ymchwil y treialon yn cyfuno ymchwil blaenllaw ac arbenigedd meddygol i ddarparu’r canlyniadau gorau posibl ar gyfer cleifion canser. Yn gartref i academyddion blaenllaw gan gynnwys ymchwilwyr, rheolwyr treialon, rheolwyr data ac ystadegwyr, mae’n rhan hanfodol o rhwydwaith ymchwil Ymchwil Canser y DU, sy’n helpu i lunio tirwedd ymchwil clinigol yn y DU ac yn rhyngwladol.

Yn ôl yr Athro Richard Adams, Cyfarwyddwr Treialon Canser Caerdydd: “Rydym yn falch iawn bod Prifysgol Caerdydd wedi cael y grant hwn. Mae ein gwaith ymchwil clinigol yn ein galluogi i gyfieithu darganfyddiadau o’r labordy a gwella triniaethau canser, gan roi’r cyfle gorau i fwy o gleifion o drechu eu hafiechydon.

Aeth ymlaen: “Mae treialon clinigol yn hanfodol ar gyfer profi triniaethau newydd. Er enghraifft, rydym yn cynnal treialon mewn canser oesoffagaidd, canserau’r pen a’r gwddf a chanserau’r gwaed.”

Mae'r ymchwil yn cynnwys y prawf AML19 ar gyfer oedolion ifanc â Lewcemia Myeloid Acíwt (AML) – math ymosodol o ganser y gwaed.

Yn ôl yr Athro Robert Hills, Dirprwy Gyfarwyddwr Treialon Canser Caerdydd, sy'n arwain y treialon lewcemia: “O ganlyniad i'n gwaith ymchwil, rydym wedi gweld trawsnewid yn y ffordd y gellir trin y math hwn o ganser.

Mae’r cyhoeddiad diweddaraf ynghylch ariannu yn dilyn adolygiad mawr gan yr elusen o’i holl Unedau Treialon Canser Ymchwil Canser y DU. Canlyniad hyn yw buddsoddi £45m mewn wyth uned ar draws y DU, un o fuddsoddiadau mwyaf yr elusen mewn ymchwil clinigol hyd yn hyn.

Cynhaliwyd yr adolygiad gan banel rhyngwladol o arbenigwyr ac roedd y gystadleuaeth yn un ffyrnig.

Dywedodd Ruth Amies, llefarydd Cancer Research UK ar gyfer Cymru: “Mae’r buddsoddiad hanfodol hwn yn cydnabod yr ymchwil ardderchog sy’n digwydd yng Nghaerdydd. Mae'n sicrhau gall ymchwilwyr fanteisio i'r eithaf ar ein darganfyddiadau gwyddonol mwyaf addawol ac yn eu trosi i'r profion newydd a thriniaethau ar gyfer cleifion.

“Caiff un ym mhob dau ohonom ddiagnosis o ganser ar ryw adeg yn ystod ein bywydau, felly mae’n galonogol i wybod – gyda diolch i’n cefnogwyr – bod Ymchwil Canser y DU yn gallu ariannu peth o’r ymchwil gorau a mwyaf addawol yma yng Nghymru, i helpu mwy o bobl i oroesi.

Aeth Ruth yn ei blaen: “Mae cymaint o ffyrdd o gefnogi gwaith Ymchwil Canser y DU – gwaith sy’n achub bywydau – o ymrestru ar gyfer Walk All Over Cancer ym mis Mawrth i redeg y Ras am Oes, gyda digwyddiadau’n cael eu cynnal o amgylch Cymru o fis Mai i fis Medi; neu roi o’ch amser i wirfoddoli yn ein siopau.”

“Mae’r nifer o bobl sy’n goroesi wedi dyblu ers y 1970au cynnar a bu gwaith Ymchwil Canser y DU wrth wraidd y cynnydd hwnnw – fodd bynnag, mae pob cam a gymerir gan ein doctoriaid, nyrsys a gwyddonwyr yn ddibynnol ar roddion gan y cyhoedd a’r gwaith codi arian diflino ar ran ein cefnogwyr.”

Researchers are set to receive a major cash boost for pioneering research into cancer.

Cancer Research UK is investing more than £5.5m over the next five years in ground-breaking work at the Centre for Trials Research.

The grant will allow doctors and scientists to continue researching and testing better and kinder treatments for patients.

The Centre for Trials Research combines world-class research and medical expertise to provide the best possible results for cancer patients.

The Centre for Trials Research at Cardiff University is home to leading academics including researchers, trial managers, data managers and statisticians and has the largest group of academic clinical trials staff in Wales.

Research includes the AML19 trial for young adults with Acute Myeloid Leukaemia (AML) – an aggressive type of blood cancer.

Every day, around 52 people are diagnosed with cancer in Wales.

Cancer Research UK’s Cancer Trials Units specialise in the design, delivery and analysis of trials that bring the latest scientific developments to patients all over the UK. They are a vital part of the charity’s research network, helping shape the clinical research landscape in the UK and internationally.

The Cancer Trials Units aim to bring better treatments to cancer patients in the UK faster through both adult and children’s networks.

The latest funding announcement follows a major review by the charity of all its Cancer Research UK Cancer Trials Units. This has resulted in £45million being invested into eight units across the UK, one of the charity’s largest investments in clinical research to date.

The review was conducted by an international panel of experts and the competition was fierce.

Ruth Amies, Cancer Research UK spokesperson for Wales, said: “This crucial investment recognises the fantastic research taking place in Cardiff. It ensures researchers can take full advantage of our most promising scientific discoveries and translate them into new tests and treatments for patients.

“One-in-two of us will be diagnosed with cancer at some point in our lives - so it’s reassuring to know that, thanks to our supporters, Cancer Research UK is able to fund some of the best and most promising research here in Wales, to help more people survive.

Ruth continued: “There are so many ways to support Cancer Research UK’s lifesaving work, from signing up to Walk All Over Cancer in March to entering Race for Life, with events taking place at locations all around Wales from May through to September; or giving time to volunteer in our shops.”

“Survival has doubled since the early 1970s and Cancer Research UK’s work has been at the heart of that progress – but every step our doctors, nurses and scientists take relies on donations from the public and the tireless fundraising of our supporters.”

Public lecture - all welcome

Professor Richard Adams will be delivering his inaugural professorial lecture about evolving clinical research in bowel cancer on 22 March 2018, which is free and open to all members of the public. For more information and to register, please visit https://richardadams.eventbrite.co.uk

A new health check project designed to improve cancer symptom awareness and help-seeking in Yorkshire’s deprived communities has been launched today.

Researchers from Cardiff University, funded by a £486,000 award from Yorkshire Cancer Research, are carrying out a trial to find out if an interactive online health check questionnaire can increase early diagnosis in areas of South and West Yorkshire. Early diagnosis can lead to better outcomes, including improved rates of survival. The health checks will also be carried out in similar areas in South Wales.

The trial will focus on people living in areas of high deprivation because cancer outcomes tend to be worse in these communities. The reasons behind this include higher levels of unhealthy behaviours, such as smoking and drinking alcohol, poor knowledge and awareness of symptoms, and barriers in access to healthcare.

These factors often lead to diagnosis through emergency routes, such as A&E or emergency GP referral. Patients diagnosed with cancer through an emergency route are more likely to be diagnosed at a late stage, which can mean that treatment options are limited and chances of survival are lower.

The health checks will be delivered by trained lay advisors in towns and cities including Doncaster, Barnsley, Rotherham, Sheffield and Wakefield. Members of the public aged over 40 will be recruited from a variety of settings, including community venues, GP surgeries and pharmacies.

Supported by a lay advisor, people who take part in the health check will be asked questions about their background, lifestyle and health. They will then be provided with a summary page which colour codes their responses using a traffic light system (red, amber and green) to highlight areas where action or advice should be taken.

Louise Padgett, Health Check Advisor, said: “Participants in the study will be asked to complete three questionnaires – one when recruited, one two weeks later and then another six months later. We will ask them about their knowledge of symptoms as well as some background health information and their readiness to seek medical help and advice.

“The questionnaires will then be analysed to find out if the checks have increased symptom awareness. One to one interviews will also be carried out to learn more about how the health checks work in practice.”

The research is being led by health psychologist Dr Kate Brain, Screening, Prevention & Early Diagnosis Lead at Cardiff University’s Division of Population Medicine.

The health check team will be at Intake Community Library, Doncaster, today, Goldthorpe Community Shop, Barnsley, on Monday, January 22, and Athersley Community Shop, Barnsley, on Thursday, January 25.

Background

The Study Within a Trial (SWAT) programme was created to address methodological gaps in the way trials are conducted: specifically, the way trials are conducted is not always based on evidence. A SWAT is a study which aims to understand what works best in running trials.

One example is SWAT 17 that looks at evaluating the effects on recruitment of following up initial participant invitation letters with a letter or a telephone call (Lesley Anderson and Glen Titmarsh, January 1 2012 - 1547). Researchers with an idea for a SWAT can upload a study protocol to the SWAT Store, an online repository which can be accessed by all, and other trialists can take the protocol and implement it in their current clinical trials. In this way, the same research question can be asked across several trials, so providing an increased sample size and enhanced generalisability.

SWAT 66

Along with colleagues Professor Kerry Hood and Dr Mark Kelson, Claire Nollett recently published to the SWAT Repository Store SWAT 66 entitled ‘Site visits to initiate recruitment in a clinical trial: Does it matter who conducts the visit?’. This is a follow on from the first SWAT published and examines whether it is important who makes a site visit to encourage a site to start recruitment.

It is common for trial managers to experience trials in which a site has been initiated but hasn’t started recruitment; in some circumstances trial managers may pay them a visit to find out why and how to get them started. Claire and fellow researchers are interested to know if it makes a difference to successful study step up depending on whether the sites are visited by a member of the research team or a clinical peer eg. GP to GP.

Get involved

Any trial facing this problem can implement our SWAT protocol and contribute the findings to the SWAT team, thus helping to provide an evidence base for ways to improve recruitment across trials.

A full article about the SWAT has also been published in the Journal of Evidence Based Medicine.

For further information please contact Claire Nollett at nollettcl@Cardiff.ac.uk

Mae Prifysgol Caerdydd wedi’i dewis yn bartner ymchwil mewn menter gwerth £4.85m er mwyn helpu i wella bywydau plant sydd mewn perygl o gael eu cam-drin neu eu hesgeuluso.

Mae’r Adran Addysg wedi enwi Canolfan Datblygu Ymchwil Gwasanaethau Cymdeithasol i Blant (CASCADE) – sy’n rhan o Ysgol y Gwyddorau Cymdeithasol – fel ei bartner ymchwil ar gyfer y Ganolfan Beth sy’n Gweithio ar gyfer Gofal Cymdeithasol i Blant.

Bydd y Ganolfan newydd yn datblygu sail dystiolaethol gref ar ymyriadau effeithiol a systemau ymarfer ym maes gofal cymdeithasol i blant, gan edrych ar gefnogaeth i blant o'r pwynt cyfeirio hyd at fabwysiadu, cymorth wrth adael gofal a help cynnar wedi'i dargedu, ymhlith meysydd eraill.

Bydd yn dwyn ynghyd arbenigwyr blaenllaw o Ganolfan Datblygu a Gwerthuso Ymyriadau Cymhleth y Brifysgol er mwyn gwella Iechyd y Cyhoedd (DECIPHer), y Ganolfan Treialon Ymchwil, yr Uned Defnydd Systematig o Dystiolaeth Ymchwil a’r Ysgol Meddygaeth. Bydd Prifysgol Warwick yn darparu arbenigedd mewn gwerthusiad economaidd.

Yn ôl yr Athro Donald Forrester o Ganolfan Ymchwil a Datblygu Gofal Cymdeithasol i Blant (CASCADE) ym Mhrifysgol Caerdydd a Chyfarwyddwr Ymchwil newydd y Ganolfan Beth sy’n Gweithio: "Pleser o’r mwyaf yw cael cymryd rhan yn y fenter bwysig hon..."

Bydd y Ganolfan Beth sy’n Gweithio newydd yn galluogi gwyddonwyr cymdeithasol blaenllaw i werthuso argaeledd ac ansawdd tystiolaeth sy’n sail i ymyriadau polisi cyhoeddus; cymharu effeithlonrwydd dulliau gweithredu newydd ac ymarfer arferol; bydd hefyd yn cynghori’r rheini sy’n comisiynu ac yn ymgymryd ag ymyriadau i sicrhau y gellir gwerthuso eu gwaith yn effeithiol.

Mae'n rhan o gynlluniau ehangach Llywodraeth y DU i ddatblygu arfer gwell ym maes gofal cymdeithasol i blant, gyda chefnogaeth £200 miliwn yn y Rhaglen Arloesedd.

Yn ôl y Gweinidog dros Blant a Theuluoedd, Robert Goodwill,: “Mae pob plentyn yn haeddu’r gefnogaeth a’r gofal gorau posibl. Dyma pam yr ydym yn buddsoddi £200 miliwn yn y Rhaglen Arloesedd er mwyn helpu sefydliadau i yrru gwelliannau ym maes gofal cymdeithasol i blant.

"Bydd gan ganolfan What Works rôl bwysig wrth ddatblygu tystiolaeth er mwyn gwella deilliannau i blant yn ogystal â darparu arloesedd cost-effeithiol. Rydw i wrth fy modd bod Prifysgol Caerdydd wedi cael ei dewis ar gyfer y bartneriaeth ymchwil hon..."

Nod y Ganolfan – sydd wrth y camau cyntaf ar hyn o bryd – yw tyfu i fod yn sefydliad cwbl annibynnol erbyn haf 2020.

Mae’r Ganolfan Beth sy’n Gweithio bresennol yn cynnwys y Sefydliad Cenedlaethol dros Ragoriaeth mewn Iechyd a Gofal (NICE), y Sefydliad Gwaddol Addysg (EEF); y Sefydliad Ymyrraeth Gynnar; Canolfan Beth sy’n Gweithio er Gostwng Troseddu; a’r Ganolfan er Heneiddio’n Well.

Bydd y Brifysgol yn gweithio gyda Nesta, y dyfarnwyd y cytundeb iddi i ddarparu canolfan Beth sy’n Gweithio fis diwethaf.

Professor Kerry Hood, Director of the Centre for Trials Research at Cardiff University, has won the outstanding contribution to leadership award. The award is for the person who:

By their energy, enthusiasm and motivation, this individual inspires and empowers others to achieve their goals and fulfil their potential. The award is open to individuals at any level who have a leadership responsibility and includes all types of line-managers and supervisors.

Vision

Ten years ago, Kerry’s vision created the South East Wales Trials Unit. In the last three years Kerry has formed the Centre for Trials Research. From ten staff in 2006 to over 130 research staff today, the Centre is now a critical hub in Wales and the UK for clinical research. Meeting the highest research standards as evidenced by its on-going registration as a UKCRC trials unit, she has set the agenda for a research portfolio driven to maximise patient and public benefit for Wales and beyond.

Embedding core values

Kerry’s creation of Centre for Trials Research from three existing units was based explicitly on values elicited from its membership. She engaged existing staff through an open communication strategy of structured consultation and crucially devolved responsibilities to maximise ownership by staff. She brought together cross-cutting teams for Professional Services, Quality Assurance and Information Systems & Database Development while maintaining a regulatory compliant governance system. Kerry’s principled, open, solution-focused leadership approach ensures her door is always open, whenever needed.

Maintaining research expertise

Yet Kerry has managed to maintain her own research interests, currently co-applicant on £34M of research grants and over 200 publications. Her principled and passionate leadership for research inclusion has established Cardiff’s position as a leading centre for research with people with learning disabilities. Evidence of her international reputation includes her position on the NIHR Commissioning Board, as a Health & Care Research Wales Senior Research Leader, and her 2017 address to the BMJ Board Annual Strategy meeting on future directions in global research.

Benefits to Cardiff University, students and staff

Centre for Trials Research provides immense professional and scientific opportunities for all its staff, for example, through its sustained growth trajectory, the conversion from fixed to on-going staff contracts and creation of a leadership team including four new professors. Centre for Trials Research critically supports REF through collaborations across all Schools in its College, across Colleges within Cardiff and through its consultancy service supports the development of new researchers in health and social care professionals in SE Wales. Staff are attracted to the Centre through its international reputation, existing staff are retained through the opportunities championed by Kerry own commitments to equity, development, equity, transparency, research integrity and research excellence.

The Centre for Trials Research is the largest group of academic clinical trials staff in Wales.

Mae’r Athro Syr Mansel Aylward, cyn-gadeirydd Iechyd Cyhoeddus Cymru a chyn-gyfarwyddwr y Ganolfan Ymchwil Seicogymdeithasol ac Anabledd ym Mhrifysgol Caerdydd, wedi’i benodi’n Gadeirydd newydd Canolfan Gwyddorau Bywyd Cymru Cyfyngedig.

Wedi ei lansio yn 2014, mae'r Hwb Gwyddorau Bywyd wedi dod yn ganolbwynt y sector gwyddorau bywyd yng Nghymru. Gan ddod ag academyddion, gwasanaethau busnes a chlinigol a phroffesiynol at ei gilydd, mae'r hwb yn cynnwys pob gweithgarwch o fewn y sector, o ariannu i gymorth busnes i ddatblygu rhyngwladol.

Fel rhan o'i benodiad newydd, bydd yr Athro Aylward yn arwain ar ddatblygu gweledigaeth a chenhadaeth newydd ar gyfer yr Hwb, gan gynnwys darparu cyfleoedd i ehangu cwmpas yr Hwb Gwyddorau Bywyd a sicrhau bod cysylltiad rhwng y GIG a Diwydiant.

“O nerth i nerth”

Wrth groesawu'r Cadeirydd newydd, dywedodd Julie James: “Mae'r sector gwyddorau bywyd yng Nghymru wedi mynd o nerth i nerth yn ddiweddar, gan gyflawni llawer mwy na'r disgwyl ar y llwyfan rhyngwladol ac mae bellach werth oddeutu £2 biliwn i economi Cymru.

“Yr hyn sy'n allweddol i'r llwyddiant hwnnw ac i sbarduno arloesedd ar draws y sector fu Hwb Gwyddorau Bywyd Cymru Cyf ac rwy'n falch bod yr Athro Syr Mansel Aylward wedi derbyn fy ngwahoddiad i fod yn Gadeirydd ei Fwrdd...”

Wedi treulio ei yrfa yn gweithio ar draws y sector, daw yr Athro Aylward â gwybodaeth a phrofiad i'r swydd.

Meddai: “Mae'n anrhydedd imi ac rwyf yn falch iawn o gael fy mhenodi yn Gadeirydd yr Hwb Gwyddorau Bywyd...”

“Hefyd, mae'n rhaid i'r Hwb ffynnu fel elfen allweddol o weledigaeth Llywodraeth Cymru i gyflymu gweithgarwch datblygu economaidd o fewn y sector gwyddorau bywyd, trwy wneud mwy i annog ystod eang o sefydliadau ar draws y diwydiant, academia, GIG Cymru a buddsoddwyr i gydweithio i sefydlu Cymru fel un o'r amgylcheddau gorau ar y llwyfan rhyngwladol o ran arloesedd, menter ac arfer gorau yn y sector hwn.

“Heb anghofio fy mod hefyd yn ei ystyried yn bwysig i sicrhau bod amcanion a nodau yr Hwb Gwyddorau Bywyd yn cyd-fynd â nifer o amcanion Deddf Llesiant Cenedlaethau'r Dyfodol. Byddaf yn ymrwymo ac yn ymdrechu fel Cadeirydd i gyflawni'r amcanion hyn ac yn awyddus iawn i geisio arwain a llywodraethu'r Bwrdd a'i hybu i sicrhau llwyddiant yr Hwb Gwyddorau Bywyd gyda'i hamcanion newydd.”

Bydd yr Athro Aylward yn dechrau ar ei swydd newydd fel Cadeirydd ym mis Hydref 2017.